Genmab: Carcinoma, Non-Small-Cell Lung trials
The registry lists 11 Carcinoma, Non-Small-Cell Lung studies with Genmab as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 6Phase 2 10No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerRecruitingNCT07288177Phase 2
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
- PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2Results posted
- A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
- GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03576131Phase 1/2Results posted
- Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02988817Phase 1/2Results posted
- Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung CancerTerminatedNCT00460551Phase 2Results posted
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2
- Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingNCT04083599Phase 1/2
- Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase InhibitorsWithdrawnNCT01449357Phase 2